Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab plus methotrexate in very early inflammatory arthritis
2006-002787-26Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab and methotrexate in autoimmune arthritis (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Clinical remission at end of infliximab therapy. Started Jul 2006; status: completed.
02
Drugs
infliximabmethotrexate
03
Conditions
autoimmune arthritis
Beyond the preview
Go deeper on 2006-002787-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002787-26.